LncRNA SNHG6 Upregulates KPNA5 to Overcome Gemcitabine Resistance in Pancreatic Cancer via Sponging miR-944

Gao, Ge; Li, Xin; Wu, Hui; Huang, Lanlan; Lin, Yu-xin; Huo, Zhi; Xiang, Zhongyuan; Zhou, Xiao

doi:10.3390/ph16020184

Cited by 5 publications

(3 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is generally accepted that lncRNAs exert their biological roles by acting as miRNA sponges and forming an lncRNA–miRNA–mRNA axis 29 . SNHG6 sponges miR‐944 and promotes KPNA5 expression, thereby weakening gemcitabine resistance in pancreatic cancer 30 . In addition, SNHG6 enhances hyperoxia‐induced lung cell injury via miR‐335‐KLF5 27 .…”

Section: Discussionmentioning

confidence: 99%

Suppression of long noncoding RNA SNHG6 alleviates cigarette smoke‐induced lung inflammation by modulating NF‐κB signaling

Yang,

Yuan,

Wang

et al. 2024

Environmental Toxicology

View full text Add to dashboard Cite

BackgroundChronic obstructive pulmonary disease (COPD) is a widespread inflammatory disease with a high mortality rate. Long noncoding RNAs play important roles in pulmonary diseases and are potential targets for inflammation intervention.MethodsThe expression of small nucleolar RNA host gene 6 (SNHG6) in mouse lung epithelial cell line MLE12 with or without cigarette smoke extract (CSE) treatment was first detected using quantitative reverse‐transcription PCR. ELISA was used to evaluate the release of inflammatory cytokines (TNF‐α, IL‐1β, and IL‐6). The binding site of miR‐182‐5p with SNHG6 was predicted by using miRanda, which was verified by double luciferase reporter assay.ResultsHere, we revealed that SNHG6 was upregulated in CS‐exposed MLE12 alveolar epithelial cells and lungs from COPD‐model mice. SNHG6 silencing weakened CS‐induced inflammation in MLE12 cells and mouse lungs. Mechanistic investigations revealed that SNHG6 could upregulate IκBα kinase through sponging the microRNA miR‐182‐5p, followed by activated NF‐κB signaling. The suppressive effects of SNHG6 silencing on CS‐induced inflammation were blocked by an miR‐182‐5p inhibitor.ConclusionOverall, our findings suggested that SNHG6 regulates CS‐induced inflammation in COPD by activating NF‐κB signaling, thereby offering a novel potential target for COPD treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Suppression of long noncoding RNA SNHG6 alleviates cigarette smoke‐induced lung inflammation by modulating NF‐κB signaling

Yang,

Yuan,

Wang

et al. 2024

Environmental Toxicology

View full text Add to dashboard Cite

show abstract

“…[9] A previous study elucidated the involvement of lncRNAs in the development and treatment of PAAD as carcinogenic factors or tumor suppressors, thus highlighting lncRNAs as potential diagnostic and therapeutic targets. [10][11][12][13] It is now generally believed that genomic instability may have greater diagnostic potential for early detection of cancer. [14] Recent studies have found that molecular subtypes of pancreatic cancer are associated with specific copy number abnormalities of mutated genes such as Kirsten rat sarcoma viral oncogene homolog (KRAS).…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The potential use and experimental validation of genomic instability-related lncRNA in pancreatic carcinoma

Xia,

Zhao,

Song

et al. 2023

Medicine

View full text Add to dashboard Cite

This study explored the potential role of long noncoding RNA (lncRNAs) associated with genomic instability in the diagnosis and treatment of pancreatic adenocarcinoma (PAAD). Transcriptome and single-nucleotide variation data of PAAD samples were downloaded from the cancer genome atlas database to explore genomic instability-associated lncRNAs. We constructed a genomic instability-associated lncRNA prognostic signature. Then gene ontology and Kyoto encyclopedia of genes and genomes enrichment analyses were used to explore the physiological role of lncRNAs involved in genomic instability. Tumor microenvironments, immunotherapy response, immune cell infiltration, immune checkpoint, and drug sensitivity were compared between high-risk and low-risk groups. In vitro experiments were performed for external validation. Six lncRNAs associated with genomic instability were identified, capable of predicting the prognosis of PAAD. Patients were assigned to low-risk or high-risk groups using these biomarkers, with better or worse prognosis, respectively. The tumor immune score, immune cell infiltration, and efficacy of immunotherapy were worse in the high-risk group. A drug sensitivity analysis revealed the high- and low-risk groups had different half-maximal inhibitory concentrations. The expression of cancer susceptibility candidate 8 was significantly higher in tumor tissues than in normal tissues, while the expression of LYPLAL1-AS1 exhibited an opposite pattern. They may be potential diagnostic or prognostic biomarkers for patients with pancreatic cancer. Genomic instability-associated lncRNAs were explored in this study and predicted the prognosis of PAAD and stratified patients risk in PAAD. These lncRNAs also predicted the efficacy of immunotherapy and potential therapeutic targets in PAAD.

show abstract

lncRNAs: New players of cancer drug resistance via targeting ABC transporters

Ebrahimnezhad,

Asl,

Rezaie

et al. 2024

IUBMB Life

View full text Add to dashboard Cite

Cancer drug resistance poses a significant obstacle to successful chemotherapy, primarily driven by the activity of ATP‐binding cassette (ABC) transporters, which actively efflux chemotherapeutic agents from cancer cells, reducing their intracellular concentrations and therapeutic efficacy. Recent studies have highlighted the pivotal role of long noncoding RNAs (lncRNAs) in regulating this resistance, positioning them as crucial modulators of ABC transporter function. lncRNAs, once considered transcriptional noise, are now recognized for their complex regulatory capabilities at various cellular levels, including chromatin modification, transcription, and post‐transcriptional processing. This review synthesizes current research demonstrating how lncRNAs influence cancer drug resistance by modulating the expression and activity of ABC transporters. lncRNAs can act as molecular sponges, sequestering microRNAs that would otherwise downregulate ABC transporter genes. Additionally, they can alter the epigenetic landscape of these genes, affecting their transcriptional activity. Mechanistic insights reveal that lncRNAs contribute to the activity of ABC transporters, thereby altering the efflux of chemotherapeutic drugs and promoting drug resistance. Understanding these interactions provides a new perspective on the molecular basis of chemoresistance, emphasizing the regulatory network of lncRNAs and ABC transporters. This knowledge not only deepens our understanding of the biological mechanisms underlying drug resistance but also suggests novel therapeutic strategies. In conclusion, the intricate interplay between lncRNAs and ABC transporters is crucial for developing innovative solutions to combat cancer drug resistance, underscoring the importance of continued research in this field.

show abstract

LncRNA SNHG6 Upregulates KPNA5 to Overcome Gemcitabine Resistance in Pancreatic Cancer via Sponging miR-944

Cited by 5 publications

References 45 publications

Suppression of long noncoding RNA SNHG6 alleviates cigarette smoke‐induced lung inflammation by modulating NF‐κB signaling

Suppression of long noncoding RNA SNHG6 alleviates cigarette smoke‐induced lung inflammation by modulating NF‐κB signaling

The potential use and experimental validation of genomic instability-related lncRNA in pancreatic carcinoma

lncRNAs: New players of cancer drug resistance via targeting ABC transporters

Contact Info

Product

Resources

About